For the year ending 2025-12-31, IDYA had $28,657K increase in cash & cash equivalents over the period. -$73,466K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -113,698 |
| Depreciation and amortization | 2,700 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | 9,976 |
| Stock-based compensation | 46,115 |
| Amortization of right of use assets | 1,893 |
| Accounts receivable | 0 |
| Prepaid expenses and other assets | 7,840 |
| Accounts payable | 2,697 |
| Accrued and other liabilities | 10,427 |
| Contract assets and liabilities | 5,973 |
| Lease liabilities | 2,557 |
| Net cash used in operating activities | -71,098 |
| Purchases of property and equipment, net | 2,368 |
| Purchases of marketable securities | 607,889 |
| Maturities of marketable securities | 680,233 |
| Net cash provided by (used in) investing activities | 69,976 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 0 |
| Proceeds from issuances of pre-funded warrants | 0 |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | 24,855 |
| Proceeds from exercise of common stock options | 3,431 |
| Proceeds from espp purchases | 1,493 |
| Net cash provided by financing activities | 29,779 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,657 |
| Cash and cash equivalents at beginning of period | 85,183 |
| Cash and cash equivalents at end of period | 113,840 |
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)